Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China
China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the...
Potential first-in-class
Aosaikang Receives FDA Approval for ASKG915 Clinical Trial
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...
Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting
China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced that the Phase II clinical study for its...
Yifan Pharmaceutical Licenses F-627 to Acrotech for US Distribution
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the establishment of a licensing agreement with...
Hope Medicine Gains Global Approval for Phase II Trial of HMI-115
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...
Bliss Bio’s BB-1709 Accepted for Review by China’s CDE
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...
Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...
Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab
Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...
Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval
Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...
Ocumension Initiates Second Phase III Denali Study for OT-301 in US
China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...
Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer
Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced the first patient dosing in a global...
Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...
RemeGen’s Telitacicept Gains EU, China Approvals for Global Phase III Study
China-based pharma firm RemeGen (HKG: 9995) has announced receiving approvals from authorities in the European...